Goldman Sachs Analyst Reiterates Neutral Rating on Halozyme Therapeutics with Lowered Price Target
On January 18, 2024, Graig Suvannavejh, an analyst at Goldman Sachs, reiterated his Neutral rating on Halozyme Therapeutics (NASDAQ: HALO) ...
On January 18, 2024, Graig Suvannavejh, an analyst at Goldman Sachs, reiterated his Neutral rating on Halozyme Therapeutics (NASDAQ: HALO) ...
StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.
© 2023 StocksToday.com